News & Events
June 15, 2021 - June 16, 2021
Design of Clinical Trials in New-Onset Type 1 Diabetes: Regulatory Considerations for Drug DevelopmentCritical Path Institute invites you to the upcoming free virtual workshop, Design of Clinical Trials in New-Onset Type 1 Diabetes: Regulatory Considerations for Drug Development, June 15-16, 2021. The purpose of this scientific workshop is to discuss the existing evidence regarding the role of C-peptide in clinical trials intended to support regulatory decision making, unique regulatory considerations......
March 10, 2021
View Now: IBD Biomarker Regulatory Science WebinarWednesday, March 10, 10 a.m. ET The 3TR IMI project consortium and Critical Path Institute invite you to participate in the IBD Biomarker Regulatory Science Webinar. Together, with a collection of public research institutes, industry members and patient advocates, we will align on how to progress biomarkers through the FDA & EMA’s regulatory acceptance process. This webinar......
February 9, 2021 - February 11, 2021
SHIP-MD 2021 Virtual Workshop
Join Us February 9th, 10th, 11th 2021
Free Public Virtual Meeting and Workshop
All stakeholders interested in pediatric medical device development are invited to a dynamic 3-day virtual public meeting developed and guided by a multi-stakeholder group including C-Path, the U.S. Food and Drug Administration, AdvaMed, American Academy of Pediatrics, and leaders of pediatric health systems.
October 27, 2020
Critical Path for Alzheimer’s Disease 2020 Annual Meeting and Regulatory Science Workshop – VirtualOctober 27, 2020 9:30 a.m. – 1:00 p.m. (US Eastern Time) The Critical Path for Alzheimer’s Disease (CPAD) is a Critical Path Institute public-private partnership aimed at generating actionable solutions and knowledge towards advancing drug development across the AD continuum. The key objectives of the meeting are: Scientific dialogue to guide the strategic development of......
September 15, 2020
Drug Development and Regulation in the Age of Precision Medicine
An introduction and overview of the Critical Path Institute and University of Arizona collaboration and the regulatory science graduate program and courses. Plus, a deep dive into precision medicine as a disruptive force across all aspects of the health care system. Specifically, how the development of precision medicine based-therapies continue to pose challenges related to scientific discovery, diagnostic regulatory policy, investment incentives, coverage and reimbursement, and the implementation of new technologies into clinical practice.
Presenters: John-Michael Sauer, PhD, C-Path Biomarker Program Officer and Executive Director of the Predictive Safety Testing Consortium
Tara Sklar, JD, MPH, Professor of Health Law, Director, Health Law & Policy Program
Part of Arizona Bioscience Week Educational Events | Register for AZBW 2020